Interview

INOVIQ says the findings reinforce the broader potential of its off-the-shelf cell-free CAR exosome platform, which has now shown activity in triple-negative breast cancer, non-small cell lung cancer, and ovarian cancer.

The company presented the findings at the International Mental Health Conference on the Gold Coast and described clinically significant reductions in depression and trauma symptoms alongside improvements in quality of life and daily functioning.

AFT Pharmaceuticals has announced that the US Food and Drug Administration has reviewed and allowed the company’s Investigational New Drug application for its injectable iron project to proceed to a global Phase 3 clinical trial.

Neurizon Therapeutics this week disclosed new preclinical data for its lead ALS candidate, NUZ-001, that the company will present at the BIO International Convention 2026.

Avecho Biotechnology has moved a major step closer to completing its pivotal Phase 3 study of a TPM-enhanced cannabidiol capsule for insomnia after an independent Data Monitoring Board unanimously recommended that the trial continue with its originally planned enrolment of 519 participants.

UniQuest and the Ellison Medical Institute have signed an exclusive licence that could push a promising University of Queensland treatment for advanced prostate cancer into first-in-human trials as early as 2027.

Tetratherix has announced that its joint venture, Tutelix, has received approval from the Human Research Ethics Committee in Australia to start an international pivotal clinical trial for its hydrogel spacer.

Invion has taken a step to strengthen its clinical leadership by appointing Dr Colin Hopper, a globally recognised authority in photodynamic therapy, as a clinical advisor.

Recce Pharmaceuticals has received approval from the Human Research Ethics Committee to advance its Australian study of RECCE 327 Topical Gel to a pivotal Phase 3 trial for diabetic foot infections, a move the company says accelerates its global registration strategy.

MTPConnect has adopted a new name as it enters its second decade, rebranding itself as AUScelerate. The organisation said the change aims to better reflect its mission to commercialise Australian life sciences.

Dr Christian Toouli, CEO and Managing Director of FivepHusion, said, "The ethics approval of the Phase II DART protocol is an exciting milestone towards our goal of evaluating Deflexifol as a promising therapy for these patients."

AusBiotech has announced that Australia's Biggest Week in Biotech 2027 will be held in Brisbane from 23–27 August, marking a shift from its traditional October timing.